BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27474808)

  • 1. Peripheral blood blast clearance is an independent prognostic factor for survival and response to acute myeloid leukemia induction chemotherapy.
    Short NJ; Benton CB; Chen HC; Qiu P; Gu L; Pierce S; Brandt M; Maiti A; Min TL; Naqvi K; Quintas-Cardama A; Konopleva M; Kadia T; Cortes J; Garcia-Manero G; Ravandi F; Jabbour E; Kantarjian H; Andreeff M
    Am J Hematol; 2016 Dec; 91(12):1221-1226. PubMed ID: 27474808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prognostic value of the peripheral blood cell counts changes during induction chemotherapy in Chinese patients with adult acute myeloid leukemia.
    Huang YM; Wang YN; Zheng Y; Pan LL; Li Y; Li JG; Wang SY
    Medicine (Baltimore); 2021 Feb; 100(8):e24614. PubMed ID: 33663070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia.
    Yu C; Kong QL; Zhang YX; Weng XQ; Wu J; Sheng Y; Jiang CL; Zhu YM; Cao Q; Xiong SM; Li JM; Xi XD; Chen SJ; Chen B
    J Hematol Oncol; 2015 May; 8():48. PubMed ID: 25957890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial.
    Kern W; Haferlach T; Schoch C; Loffler H; Gassmann W; Heinecke A; Sauerland MC; Berdel W; Buchner T; Hiddemann W
    Blood; 2003 Jan; 101(1):64-70. PubMed ID: 12393605
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Time to Clearance of Peripheral Blood Blasts Predicts Complete Remission and Survival in Chinese Adults with Acute Myeloid Leukemia.
    Li X; Zhu H; Zhang Y; Zhao W; Mi J; Hu J; Li J
    Acta Haematol; 2016; 135(4):217-23. PubMed ID: 26967450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia.
    Covut F; Gupta D; Pinto R; Dambrosio N; El Jurdi N; Meyerson H; Ueda M; Kolk M; Creger R; Metheny L; Cooper BW; Caimi PF; Malek E; Otegbeye F; Lazarus HM; De Lima M; Tomlinson BK
    Clin Lymphoma Myeloma Leuk; 2019 Feb; 19(2):73-82. PubMed ID: 30528848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Parameters of Acute Myeloid Leukaemia at Presentation.
    Jahic A; Iljazovic E; Hasic S; Arnautovic AC; Sabitovic D; Mesanovic S; Sahovic H; Simendic V
    Med Arch; 2017 Feb; 71(1):20-24. PubMed ID: 28428668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early clearance of peripheral blood blasts predicts response to induction chemotherapy in acute myeloid leukemia.
    Arellano M; Pakkala S; Langston A; Tighiouart M; Pan L; Chen Z; Heffner LT; Lonial S; Winton E; Khoury HJ
    Cancer; 2012 Nov; 118(21):5278-82. PubMed ID: 22517268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bone marrow cellularity at day 14 is the most important predictive factor for response in patients with AML who require double-induction chemotherapy: Analysis from a large, single institution experience.
    Griffin PT; Komrokji RS; Sweet K; Al Ali NH; Padron E; Kubal TE; List AF; Lancet JE
    Am J Hematol; 2017 Mar; 92(3):232-237. PubMed ID: 28006850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic significance of day 14 bone marrow evaluation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Short NJ; Kantarjian HM; Sasaki K; Cortes JE; Ravandi F; Thomas DA; Garcia-Manero G; Khouri I; Kebriaei P; Champlin RE; Pierce S; Issa GC; Konopleva M; Kadia TM; Bueso-Ramos C; Khoury JD; Jain N; O'Brien SM; Jabbour E
    Cancer; 2016 Dec; 122(24):3812-3820. PubMed ID: 27508525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The prognostic significance of rapid peripheral blood blast clearance during the initial course of induction chemotherapy in young patients with de novo acute myeloid leukemia.
    Nakano H; Fujiwara SI; Ito S; Mashima K; Umino K; Minakata D; Yamasaki R; Kawasaki Y; Sugimoto M; Ashizawa M; Yamamoto C; Hatano K; Okazuka K; Sato K; Oh I; Ohmine K; Suzuki T; Muroi K; Kanda Y
    Hematol Oncol; 2017 Sep; 35(3):357-364. PubMed ID: 26639319
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The percentage of peripheral blood blasts on day 7 of induction chemotherapy predicts response to therapy and survival in patients with acute myeloid leukemia.
    Gao S; Tan Y; Liu X; Su L; Yu P; Han W; Cui J; Li W
    Chin Med J (Engl); 2014; 127(2):290-3. PubMed ID: 24438618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blast vacuolization in AML patients indicates adverse-risk AML and is associated with impaired survival after intensive induction chemotherapy.
    Ballo O; Stratmann J; Serve H; Steffen B; Finkelmeier F; Brandts C
    PLoS One; 2019; 14(9):e0223013. PubMed ID: 31568521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early peripheral blood blast clearance during induction chemotherapy for acute myeloid leukemia predicts superior relapse-free survival.
    Elliott MA; Litzow MR; Letendre LL; Wolf RC; Hanson CA; Tefferi A; Tallman MS
    Blood; 2007 Dec; 110(13):4172-4. PubMed ID: 17909077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk factors for outcome in refractory acute myeloid leukemia patients treated with a combination of fludarabine, cytarabine, and amsacrine followed by a reduced-intensity conditioning and allogeneic stem cell transplantation.
    Pfrepper C; Klink A; Behre G; Schenk T; Franke GN; Jentzsch M; Schwind S; Al-Ali HK; Hochhaus A; Niederwieser D; Sayer HG
    J Cancer Res Clin Oncol; 2016 Jan; 142(1):317-24. PubMed ID: 26424692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia.
    Song J; Shang B; Pei Y; Shi M; Niu X; Dou L; Drokow EK; Xu F; Bai Y; Sun K
    Leuk Res; 2021 Oct; 109():106638. PubMed ID: 34116372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Karyotype plus NPM1 mutation status defines a group of elderly patients with AML (≥60 years) who benefit from intensive post-induction consolidation therapy.
    Sperr WR; Zach O; Pöll I; Herndlhofer S; Knoebl P; Weltermann A; Streubel B; Jaeger U; Kundi M; Valent P
    Am J Hematol; 2016 Dec; 91(12):1239-1245. PubMed ID: 27643573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Day 14 bone marrow biopsy in predicting complete remission and survival in acute myeloid leukemia.
    Hussein K; Jahagirdar B; Gupta P; Burns L; Larsen K; Weisdorf D
    Am J Hematol; 2008 Jun; 83(6):446-50. PubMed ID: 18247382
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of patients who undergo aggressive induction therapy for secondary acute myeloid leukemia.
    Rizzieri DA; O'Brien JA; Broadwater G; Decastro CM; Dev P; Diehl L; Beaven A; Lagoo A; Gockerman JP; Chao NJ; Moore JO
    Cancer; 2009 Jul; 115(13):2922-9. PubMed ID: 19452542
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Clinical importance of morphological multilineage dysplasia in acute myeloid leukemia with myelodysplasia related changes].
    Park SH; Chi HS; Park SJ; Jang S; Park CJ
    Korean J Lab Med; 2010 Jun; 30(3):231-8. PubMed ID: 20603581
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.